In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Icecure Medical, with a price target of $3.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight Icecure Medical’s promising future. The company reported third-quarter 2025 results with revenue exceeding expectations, despite a slightly wider GAAP loss per share. Icecure is on the cusp of receiving FDA approval for its post-market study protocol, which is anticipated to drive further growth. Additionally, the ProSense system has received regulatory approval in Switzerland, and there is a growing interest in the system both in the US and internationally.
Furthermore, Icecure’s financial position is stable, with $10 million in cash and no debt, which should support operations into the second quarter of 2026. The company’s strategic expansion plans include increasing its sales team and pursuing a permanent CPT I code for broader reimbursement. The potential for ProSense in treating various medical conditions, coupled with its competitive advantages over traditional surgical methods, supports a compelling valuation. These factors collectively justify the Buy rating and a 12-month price target of $3.00.
Vendetti covers the Healthcare sector, focusing on stocks such as Lucid Diagnostics, Nuwellis, and Milestone Scientific. According to TipRanks, Vendetti has an average return of -25.0% and a 24.60% success rate on recommended stocks.